Aldactide 50

January 2002
Royal Society of Medicine: Medicines;2002, p42
Reference Entry
The article presents information on Aldactide 50, a proprietary, prescription-only compound preparation of the aldosterone-antagonist and potassium-sparing spironolactone and the thiazide-type diuretic hydroflumethiazide. This drug can be used for heart failure treatment and is available as tablets.


Related Articles

  • The creative edge.  // Sustain' Magazine;Sep/Oct2011, p23 

    The article discusses the architectural design of the company MediaCityUK in Salford, England, designed by the company Gillespies.

  • Aldactide 25.  // Royal Society of Medicine: Medicines;2002, p42 

    The article presents information on Aldactide 25, a proprietary, prescription-only compound preparation of the aldosterone-antagonist and potassium-sparing diuretic spironolactone and the thiazide diuretic hydroflumethiazide. This drug can be used for heart failure treatment, kidney disease and...

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Aldosterone Antagonists � Last Man Standing? Armstrong, Paul W. // New England Journal of Medicine;1/6/2011, Vol. 364 Issue 1, p79 

    The author reflects on aldosterone antagonists in the treatment of heart failure. It says that in the turn of the millennium, there are four cardiac medicines developed before 1960 that survived namely aspirin, digoxin, warfarin and spironolactone. It highlights two studies whose findings have...

  • Hyperkalaemia in the age of aldosterone antagonism. Chapagain, A.; Ashman, N. // QJM: An International Journal of Medicine;Nov2012, Vol. 105 Issue 11, p1049 

    Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious...

  • Spironolactone.  // Reactions Weekly;3/10/2007, Issue 1142, p21 

    The article presents a case report of a man with congestive heart failure and was receiving spironolactone daily. It states that a condition called gynecomastia which is an increasing breast size in the patient during his treatment made his medication replaced by eplerenone. The author mentions...

  • Lack of adherence in heart failure therapy.  // Healthcare Benchmarks & Quality Improvement;May2010, Vol. 17 Issue 5, p58 

    This article discusses a study which examined the adherence to recommendations for the treatment of heart failure. The study showed that about one-third of patients with heart failure had received the recommended therapy. Nancy M. Albert, director of nursing research and innovation in the...

  • Aldosterone use in heart failure.  // Infectious Disease Alert;Dec2009 Pharmacology Watch Suppleme, p1 

    The article discusses research on the clinical use of aldosterone for heart failure (HF). It references a study published in the 2009 issue of the "Journal of the American Medical Association." The study included 43,000 patients who were hospitalized due to HF between 2005 and 2007. Study...

  • Aldosterone use in heart failure.  // Clinical Cardiology Alert;Dec2009 Pharmacology Watch, p1 

    The author discusses research on the efficacy of aldosterone antagonist therapy in patients with moderate-to-severe heart failure (HF) and systolic dysfunction, published in the "Journal of the American Medical Association." The researchers observed more than 43,000 patients admitted to a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics